Press Releases

Press Releases

Date Title  
Sep 05, 2018
REDWOOD CITY, CA / ACCESSWIRE / September 5, 2018 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 35 sites globally have successfully treated over 200 patients with the next-generation Pantheris
Aug 30, 2018
Anticipated to Expand Addressable Market for Pantheris Family REDWOOD CITY, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company submitted a new 510(k) application to the
Aug 29, 2018
Extensive Intellectual Property Portfolio Now Includes 131 Patents and Applications REDWOOD CITY, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the issuance of an important
Aug 28, 2018
REDWOOD CITY, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that management of Avinger will present at the following investor conferences: Rodman & Renshaw 20th Annual Global
Aug 23, 2018
Post-Market Study Compares Pantheris OCT Imaging with IVUS for Diagnostic Imaging in Peripheral Arteries REDWOOD CITY, Calif. , Aug. 23, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it
Aug 13, 2018
REDWOOD CITY, Calif. , Aug. 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the second quarter ended June 30, 2018 . Second Quarter and Recent Highlights Revenue of $2.1 million
Aug 06, 2018
REDWOOD CITY, Calif. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), will announce its second quarter 2018 results for the period ended June 30, 2018 on Monday, August 13, 2018 after market close.
Jul 12, 2018
REDWOOD CITY, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the
Jul 10, 2018
Practicing Interventional Cardiologist is a Key Opinion Leader in the Treatment of Peripheral Artery Disease REDWOOD CITY, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the
Jun 26, 2018
REDWOOD CITY, Calif. , June 26, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that several physicians have successfully treated over 40 patients in the US across 13 sites with the